Literature DB >> 12126905

Co-immunisation with a plasmid DNA cocktail primes mice against anthrax and plague.

E D Williamson1, A M Bennett, S D Perkins, R J Beedham, J Miller, L W J Baillie.   

Abstract

The protective antigen (PA) of Bacillus anthracis and the V antigen of Yersinia pestis are potent immunogens and candidate vaccine sub-units. When plasmid DNA encoding either PA or V antigen was used to immunise the Balb/c mouse, a low serum IgG titre was detected (log (10)1.0 or less) which was slightly increased by boosting with plasmid DNA. However, when mice immunised with plasmid DNA were later boosted with the respective recombinant protein, a significant increase in titre (up to 100-fold) was observed. Mice primed with a combination of each plasmid and boosted with a combination of the recombinant proteins, were fully protected (6/6) against challenge with Y. pestis. This compared favourably with mice primed only with plasmid DNA encoding the V antigen and boosted with rV, which were partially protected (3/6) against homologous challenge or with mice primed and boosted with plasmid DNA encoding the V antigen which were poorly protected (1/6). Combined immunisation with the two plasmid DNA constructs followed by boosting with a combination of the encoded recombinant proteins enhanced the protective immune response to Y. pestis compared with priming only with plasmid DNA encoding the V antigen and boosting with rV. This enhancement may be due to the effect of CpG motifs known to be present in the plasmid DNA construct encoding PA.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12126905     DOI: 10.1016/s0264-410x(02)00232-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

Review 1.  Plague Vaccines: Status and Future.

Authors:  Wei Sun
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

Review 2.  Vaccine adjuvants: current challenges and future approaches.

Authors:  Jennifer H Wilson-Welder; Maria P Torres; Matt J Kipper; Surya K Mallapragada; Michael J Wannemuehler; Balaji Narasimhan
Journal:  J Pharm Sci       Date:  2009-04       Impact factor: 3.534

3.  Effective protective immunity to Yersinia pestis infection conferred by DNA vaccine coding for derivatives of the F1 capsular antigen.

Authors:  Haim Grosfeld; Sara Cohen; Tamar Bino; Yehuda Flashner; Raphael Ber; Emanuelle Mamroud; Chanoch Kronman; Avigdor Shafferman; Baruch Velan
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

4.  Adenovirus-mediated delivery of an anti-V antigen monoclonal antibody protects mice against a lethal Yersinia pestis challenge.

Authors:  Carolina Sofer-Podesta; John Ang; Neil R Hackett; Svetlana Senina; David Perlin; Ronald G Crystal; Julie L Boyer
Journal:  Infect Immun       Date:  2009-01-05       Impact factor: 3.441

5.  A Bivalent Anthrax-Plague Vaccine That Can Protect against Two Tier-1 Bioterror Pathogens, Bacillus anthracis and Yersinia pestis.

Authors:  Pan Tao; Marthandan Mahalingam; Jingen Zhu; Mahtab Moayeri; Michelle L Kirtley; Eric C Fitts; Jourdan A Andersson; William S Lawrence; Stephen H Leppla; Ashok K Chopra; Venigalla B Rao
Journal:  Front Immunol       Date:  2017-06-26       Impact factor: 7.561

6.  Development of a multiple-antigen protein fusion vaccine candidate that confers protection against Bacillus anthracis and Yersinia pestis.

Authors:  Theresa B Gallagher; Gabriela Mellado-Sanchez; Ana L Jorgensen; Stephen Moore; James P Nataro; Marcela F Pasetti; Les W Baillie
Journal:  PLoS Negl Trop Dis       Date:  2019-08-20

Review 7.  Developing vaccines to counter bioterrorist threats.

Authors:  Daniel M Altmann
Journal:  Expert Rev Vaccines       Date:  2005-06       Impact factor: 5.217

8.  Protective immunity against respiratory tract challenge with Yersinia pestis in mice immunized with an adenovirus-based vaccine vector expressing V antigen.

Authors:  Maria J Chiuchiolo; Julie L Boyer; Anja Krause; Svetlana Senina; Neil R Hackett; Ronald G Crystal
Journal:  J Infect Dis       Date:  2006-09-25       Impact factor: 5.226

9.  A Comparison of the Adaptive Immune Response between Recovered Anthrax Patients and Individuals Receiving Three Different Anthrax Vaccines.

Authors:  Thomas R Laws; Tinatin Kuchuloria; Nazibriola Chitadze; Stephen F Little; Wendy M Webster; Amanda K Debes; Salome Saginadze; Nikoloz Tsertsvadze; Mariam Chubinidze; Robert G Rivard; Shota Tsanava; Edward H Dyson; Andrew J H Simpson; Matthew J Hepburn; Nino Trapaidze
Journal:  PLoS One       Date:  2016-03-23       Impact factor: 3.240

10.  A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague.

Authors:  Shixia Wang; Destin Heilman; Fangjun Liu; Theodore Giehl; Swati Joshi; Xiaoyun Huang; Te-hui Chou; Jon Goguen; Shan Lu
Journal:  Vaccine       Date:  2004-09-03       Impact factor: 3.641

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.